Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 9Thoracic 7Gastrointestinal 7Other hematologic neoplasm 6Genitourinary 5Sarcoma 4Plasma cell 4Breast 4Other neoplasm 2Head & Neck 2Gynecologic 2Dermatologic 2CNS 2Other solid neoplasm 1Myeloid 1

Conditions

Mesothelioma, Malignant 1

Interventions

Cisplatin 42Pemetrexed 31Carboplatin 28Nivolumab 21pembrolizumab 19Gemcitabine 19atezolizumab 13Etoposide 13Injections 12Ipilimumab 11Cyclophosphamide 11Radiotherapy 10Oxaliplatin 10Filgrastim 10Docetaxel 10Bevacizumab 10tislelizumab 9Vincristine 9Specimen Handling 9durvalumab 8Paclitaxel 8Capecitabine 8tremelimumab 7toripalimab 7lenvatinib 7Everolimus 7spartalizumab 6olaparib 6niraparib 6Vinorelbine 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Gene Expression Profiling × Other solid neoplasm × Clear all
NCT00541073 2011-05-17

Pemetrexed, Cisplatin, and Vitamin B12 in Treating Patients With Mesothelioma of the Chest That Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 2 Completed
60 enrolled
Other solid neoplasmThoracic

Mesothelioma, Malignant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡